resulting in regulation of transcription and cellular processes. HDAC inhibition has been shown to induce genes coding for MHC class I and class II molecules and immunologic activation molecules. Tissue microarray analysis of bladder cancer cell lines has demonstrated high HDAC expression in 40-60% of urothelial tumors. Our objective was to investigate the use of HDAC inhibitors on bladder tumors to stimulate immune mediated tumor cell destruction.
resulting in regulation of transcription and cellular processes. HDAC inhibition has been shown to induce genes coding for MHC class I and class II molecules and immunologic activation molecules. Tissue microarray analysis of bladder cancer cell lines has demonstrated high HDAC expression in 40-60% of urothelial tumors. Our objective was to investigate the use of HDAC inhibitors on bladder tumors to stimulate immune mediated tumor cell destruction.
METHODS: In vitro human bladder cancer cell lines were cultured with exposure to various HDAC inhibitors and HLA matched human T cells. The murine urothelial cell line, MB49 was also cultured with HDAC inhibitors and activated murine splenocytes. MTT assay was performed to measure cell viability. We transduced the murine tumor line to carry Firefly luciferase to allow for bioluminescence monitoring post implantation and then implanted the cells intra-vesically using a 24Fr angiocatheter delivery method. Following implantation bioluminescence signals were monitored using IVIS Lumina imaging system. Our treatment arm consisted of a single intra-vesical instillation of CI-994 for 60 minutes on post-implantation Day 6 with intraperitoneal injection of PD-1 blockade, appropriate controls were also performed. Total flux was monitored by IVIS in the treatment and control arms.
RESULTS: In Vitro analysis showed a statistically significant decrease in viable tumor cells when treated with a short course of CI-994 and then exposed to activated human T cells (p 0.0025). There was an even greater response when the T cells had received PD-1 blockade (p 0.0003). MTT assay analysis of MB49 yielded similar positive results with CI-994 treatment and T cell exposure. In vivo mice who received intravesical CI-994 in combination with intraperitoneal PD-1 blockade showed a more immediate and durable response than mice in the control arms. The average bioluminescence signal for our combination treatment arm indicates minimal to no retained tumor burden.
CONCLUSIONS: HDACs are widely expressed in urothelial cancer and inhibition of the selective HDAC inhibitor CI-994 has shown promising results in vitro and in an in vivo orthotopic model at reducing tumor burden. INTRODUCTION AND OBJECTIVES: Mild bladder hyperthermia (~43 C) can be used to improve intravesical drug delivery, to trigger payload release from systemically-administered thermally-sensitive liposomes, and to elicit immune responses. In this study we assess a novel conductive bladder heater, the Combat BRS device, in a live porcine bladder model to assess its ability to function as a heat-targeted drug delivery platform for use in bladder cancer.
Source of
METHODS: Eleven 60 kg female swine were anesthestized and catheterized with a 3-way 16 French catheter. A multidimensional and multiparametric thermal monitoring system (fiberoptic microprobes, semiconductor germanium thermistors, custom designed/ fabricated thermistor strips, and infrared cameras) was surgically implanted for high resolution 3D bladder temperature mapping. The Combat BRS device was used to heat the bladders to~43 C for 2 hours. Pigs received intravesical mitomycin C (MMC, 2 mg/mL), systemic thermally-sensitive liposomes containing doxorubicin (Dox), or both. Pharmacokinetic testing was done by measuring MMC and Dox levels in blood and tissues (bladder, lymph nodes, liver, kidney, spleen, heart, and lung) by liquid chromatography tandem-mass spectrometry (Agilent 1200 -Applied Biosciences/SCIEX API 5500 QTrap). Data acquisition and quantification was performed by Analyst 1.6.2 software.
RESULTS: Heat mapping showed consistent intravesical temperatures of 42.9 C (AE0.14) and a transmural gradient of 1.5 C across the detrusor, resulting in full thickness bladder heating >41 C. Adjacent organ and core body temperature increased only minimally, well below safety thresholds. Mean bladder tissue MMC level was 0.9 mM. Mean tissue Dox level was 117.2 mM in the bladder and 6.7 mM in the heart, a 17-fold difference. Liver, kidney, spleen, lung, and LN tissue all contained significantly lower Dox levels than the bladder.
CONCLUSIONS: The Combat BRS device effectively heated the entire bladder wall to acceptable target temperatures and with excellent temperature safety parameters. Combat BRS was able to effectively trigger the release of Dox from systemically-administered thermally-sensitive liposomes, resulting in bladder Dox levels far exceeding levels required for anti-neoplastic effects, while concurrently minimizing unwanted drug delivery to other organ sites. Heat-targeted drug delivery has the potential to make systemic chemotherapy much more effective while also dramatically improving safety. The discrepancy between phenotype and genotype is compounded further by interobserver variability in pathological grading.
Source of Funding
METHODS: Whole transcriptomic (WT) analysis of 178 bladder tumours (158 NMIBC and 20 MIBC or metastatic) was performed from formalin fixed paraffin embedded (FFPE) tissues incorporating messenger RNA expression, splice variants, gene fusion and mutation detection. In NMIBC, we used a discovery (n¼38) and 2 validation cohorts (n¼ 40 and 80). These data were integrated and tested for correlations with both pathological grading and clinical outcomes. Conventional pathological grading for both WHO 1973 (grade 1, 2 and 3) and 2004 (low grade-LG vs high grade-HG) classifications was Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e855
